A phase-2 double-blind RCT of 31 participants with fibrotic metabolic dysfunction-associated steatohepatitis (MASH) tested intermittent senolytic therapy — dasatinib 100 mg plus quercetin 1,000 mg daily for three consecutive days per week across three 7-week cycles. The primary endpoint of ≥1 fibrosis stage improvement without disease worsening was achieved in 47% of treated participants versus just 7% on placebo (P=0.02). MASH resolution occurred in 53% versus 7% (P=0.02). Single-nucleus RNA sequencing confirmed mechanistic plausibility: treated livers showed reduced senescence gene signatures, lower fibrogenic cell populations, and diminished fibrotic transcription programs.
This is a genuinely striking result. Liver fibrosis has long been considered difficult to reverse pharmacologically without addressing the primary metabolic insult, yet here a senolytic regimen — originally developed for cancer — produced histological regression in a randomized controlled design. The mechanistic data linking cellular senescence clearance to fibrosis regression in human tissue is itself novel and advances a concept previously confined to mouse models. That said, the trial enrolled only 31 participants, predominantly middle-aged diabetic men, limiting generalizability. Effect sizes are large enough to be clinically meaningful but the small N means confidence intervals are wide. Quercetin is available over the counter, raising immediate patient interest, but dasatinib is a prescription tyrosine kinase inhibitor with a non-trivial side-effect profile — adverse events affected 82% of treated participants, though all were self-limiting. Larger trials with longer follow-up and histological endpoints are essential before clinical adoption.